| Heading: |
Blood Cancer: Medical Treatments |
| Question ID: |
1744845 |
| UIN: |
16330 |
| House: |
Commons |
| Date tabled: |
2024-11-26 |
| Asking Member ID: |
5103 |
| Asking Member display name: |
Luke Taylor
|
| Asking Member handle: |
LukeTaylorLD
|
| Asking Member Twitter reference: |
@LukeTaylorLD
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure UK blood cancer patients can access effective new therapies that are available to patients overseas but have been subject to NICE terminated appraisals. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE), following an evaluation of a treatment’s co... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |